About this study The purpose of this study is to evaluate the efficacy of I-124 evuzamitide for diagnosing cardiac amyloidosis. Participation eligibility Participant eligibility includes age, gender, ...

EchoGo® Amyloidosis is the first FDA-cleared AI screening tool for cardiac amyloidosis using an echocardiogram and has received Breakthrough Device designation from the FDA. Study results demonstrate ...

Cardiac amyloidosis is an often-missed, life-threatening cause of heart failure. As new disease-modifying therapies emerge, timely and earlier diagnosis is critical.EchoGo® Amyloidosis is the ...

In a new study published in the European Heart Journal, researchers reported the successful development and validation of a medical artificial intelligence (AI) model that screens for cardiac ...

We propose a novel pipeline for the generation of synthetic full spatial cine cardiac magnetic resonance (CMR) images via a latent Denoising Diffusion Implicit Models (DDIMs). These synthetic images ...

Start With the Why Leaving the trusted environment of a primary care office can be daunting for patients, particularly for those who haven't had cardiac testing before.

Upgrade your home gym with these top-rated treadmills at unbeatable prices.

BACKGROUND: The prevalence of transthyretin cardiac amyloidosis among older adults (often octogenarians) is increasing. We aimed to determine whether age and geriatric syndromes bear any impact on the ...

Abstract This study aimed to evaluate the effects on glycemia and lactacidemia as a function of the time of intake of concentrate ration in horses before a high-speed treadmill test. Fifteen eventing ...

Platforms: rocm This test was disabled because it is failing in CI. See recent examples and the most recent trunk workflow logs. Over the past 3 hours, it has been determined flaky in 3 workflow(s) ...

Left Atrial Veno-Arterial ECMO (LAVA-ECMO) in Cardiogenic Shock as a Bridge to Surgical or Transcatheter Therapies: A Single-Center Experience Receive the the latest news, research, and presentations ...